A phase 3 randomized trial published in Blood Advances found that adding lenalidomide to standard rituximab maintenance therapy did not significantly improve 2-year progression-free survival (PFS) in older or transplant-ineligible patients with relapsed/refractory (R/R) follicular lymphoma. The study enrolled 152 patients (median age 71) who had responded to salvage immunochemotherapy, randomizing them to rituximab alone or rituximab plus lenalidomide. While the combination arm showed a numerical PFS advantage, it didn't cross the threshold for statistical significance — and came with a higher burden of serious side effects.

However, an unplanned subgroup analysis offered a notable finding: patients younger than 70 showed a striking benefit from the combination, with 2-year PFS of 96% vs. 69% for rituximab alone — a difference that was statistically significant.

By the Numbers:

• 2-year PFS: 73% (combo) vs. 64% (rituximab alone); HR 0.73, P = .183
• In patients <70 years: 2-year PFS 96% vs. 69%; HR 0.32, P = .042
• Grade 3/4 neutropenia: 40.6% (combo) vs. 11.5% (monotherapy)
• Fatal adverse events reported in 9 patients (7%) across both arms

Why it matters: Relapsed/refractory follicular lymphoma is notoriously hard to manage in older patients with limited treatment options. These findings suggest that a one-size-fits-all maintenance approach may not be optimal — and that age-stratified, personalized strategies could be key to improving outcomes while managing toxicity.